More specifically, one possible mechanism is that GLSF treatment resulted in an inhibition of the NF-kB pathway, a shared target of the aforementioned predicted upstream regulators, which eventually may lead to tumor suppression. The gene discussed is NFKB1; the disease is neoplasm.